Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions

Open access
Sos, Martin L., Michel, Kathrin, Zander, Thomas, Weiss, Jonathan, Frommolt, Peter, Peifer, Martin, Li, Danan, Ullrich, Roland, Koker, Mirjam, Fischer, Florian, Shimamura, Takeshi, Rauh, Daniel, Mermel, Craig, Fischer, Stefanie, Stückrath, Isabel, Heynck, Stefanie, Beroukhim, Rameen, Lin, William, Winckler, Wendy, Shah, Kinjal, LaFramboise, Thomas, Moriarty, Whei F., Hanna, Megan, Tolosi, Laura, Rahnenführer, Jörg, Verhaak, Roel, Chiang, Derek, Getz, Gad, Hellmich, Martin, Wolf, Jürgen, Girard, Luc, Peyton, Michael, Weir, Barbara A., Chen, Tzu-Hsiu, Greulich, Heidi, Barretina, Jordi, Shapiro, Geoffrey I., Garraway, Levi A., Gazdar, Adi F., Minna, John D., Meyerson, Matthew, Wong, Kwok-Kin, Thomas, Roman K. · 2009 · Journal of Clinical Investigation

Abstract

Somatic genetic alterations in cancers have been linked with response to targeted therapeutics by creation of specific dependency on activated oncogenic signaling pathways. However, no tools currently exist to systematically connect such genetic lesions to therapeutic vulnerability. We have therefore developed a genomics approach to identify lesions associated with therapeutically relevant oncogene dependency. Using integrated genomic profiling, we have demonstrated that the genomes of a large panel of human non-small cell lung cancer (NSCLC) cell lines are highly representative of those of primary NSCLC tumors. Using cell-based compound screening coupled with diverse computational approaches to integrate orthogonal genomic and biochemical data sets, we identified molecular and genomic predictors of therapeutic response to clinically relevant compounds. Using this approach, we showed that v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations confer enhanced Hsp90 dependency and validated this finding in mice with KRAS-driven lung adenocarcinoma, as these mice exhibited dramatic tumor regression when treated with an Hsp90 inhibitor. In addition, we found that cells with copy number enhancement of v-abl Abelson murine leukemia viral oncogene homolog 2 (ABL2) and ephrin receptor kinase and v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) (SRC) kinase family genes were exquisitely sensitive to treatment with the SRC/ABL inhibitor dasatinib, both in vitro and when it xenografted into mice. Thus, genomically annotated cell-line collections may help translate cancer genomics information into clinical practice by defining critical pathway dependencies amenable to therapeutic inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci37127

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 77 references

Cited by

See all 258

Metadata

Authors
Sos, M. L., Michel, K., Zander, T., Weiss, J., Frommolt, P., Peifer, M., Li, D., Ullrich, R., Koker, M., Fischer, F., Shimamura, T., Rauh, D., Mermel, C., Fischer, S., Stückrath, I., Heynck, S., Beroukhim, R., Lin, W., Winckler, W., Shah, K., LaFramboise, T., Moriarty, W. F., Hanna, M., Tolosi, L., Rahnenführer, J., Verhaak, R., Chiang, D., Getz, G., Hellmich, M., Wolf, J., Girard, L., Peyton, M., Weir, B. A., Chen, T.-H., Greulich, H., Barretina, J., Shapiro, G. I., Garraway, L. A., Gazdar, A. F., Minna, J. D., Meyerson, M., Wong, K.-K., & Thomas, R. K.
Venue
Journal of Clinical Investigation
Published
2009-06-01
Volume
119
Issue
6
Pages
1727-1740
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2156052827
Cited by
258
References
77
FWCI
23.12
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions. https://app.cochat.ai/papers/10.1172/jci37127
The paper
Sos, M. L., Michel, K., Zander, T., Weiss, J., Frommolt, P., Peifer, M., Li, D., Ullrich, R., Koker, M., Fischer, F., Shimamura, T., Rauh, D., Mermel, C., Fischer, S., Stückrath, I., Heynck, S., Beroukhim, R., Lin, W., Winckler, W., . . . Thomas, R. K. (2009). Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions. Journal of Clinical Investigation. https://doi.org/10.1172/jci37127

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.